{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:19:43Z","timestamp":1790752783174,"version":"4.1.0"},"reference-count":241,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.pbb.2022.173446","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T01:51:48Z","timestamp":1660701108000},"page":"173446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Clinical investigations of compounds targeting metabotropic glutamate receptors"],"prefix":"10.1016","volume":"219","author":[{"given":"Jeffrey M.","family":"Witkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal P.","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9\u201310","key":"10.1016\/j.pbb.2022.173446_bb0005","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00213-016-4501-9","article-title":"From bench to bedside: mGluR2 positive allosteric modulators as medications to treat substance use disorders","volume":"234","author":"Acri","year":"2017","journal-title":"Psychopharmacology"},{"issue":"13","key":"10.1016\/j.pbb.2022.173446_bb0010","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1471-244X-13-143","article-title":"A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia","volume":"22","author":"Adams","year":"2013","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pbb.2022.173446_bb0015","doi-asserted-by":"crossref","first-page":"758212","DOI":"10.1155\/2014\/758212","article-title":"Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison","volume":"2014","author":"Adams","year":"2014","journal-title":"Schizophr Res Treatment"},{"key":"10.1016\/j.pbb.2022.173446_bb1015","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.neuropharm.2015.11.031","article-title":"Translational neurophysiological markers for activity of the metabotropic glutamate receptor (mGluR2) modulator JNJ-40411813: Sleep EEG correlates in rodents and healthy men","volume":"103","author":"Ahnaou","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2022.173446_bb1020","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bbr.2014.05.003","article-title":"Blockade of the metabotropic glutamate (mGluR2) modulates arousal through vigilance states transitions: evidence from sleep-wake EEG in rodents","volume":"270","author":"Ahnaou","year":"2014","journal-title":"Behav. Brain Res."},{"issue":"12","key":"10.1016\/j.pbb.2022.173446_bb1005","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1017\/S1461145714000716","article-title":"Metabotropic glutamate receptor 5 binding in patients with obsessive-compulsive disorder","volume":"17","author":"Akkus","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.pbb.2022.173446_bb1010","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.biopsych.2015.02.027","article-title":"Association of long-term nicotine abstinence with normal metabotropic glutamate receptor-5 binding","volume":"79","author":"Akkus","year":"2016","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pbb.2022.173446_bb0025","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/mol.119.119032","article-title":"Detailed in vitro pharmacological characterization of clinically tested negative allosteric modulators of the metabotropic glutamate receptor 5","volume":"98","author":"Arsova","year":"2020","journal-title":"Mol Pharmacol."},{"issue":"16","key":"10.1016\/j.pbb.2022.173446_bb0030","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/jama.2019.4782","article-title":"Diagnosis and management of dementia: review","volume":"322","author":"Arvanitakis","year":"2019","journal-title":"JAMA"},{"issue":"1\u20133","key":"10.1016\/j.pbb.2022.173446_bb0035","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejphar.2005.10.051","article-title":"Suppression of alcohol self-administration and cue-induced reinstatement of alcohol seeking by the mGlu2\/3 receptor agonist LY379268 and the mGlu8 receptor agonist (S)-3,4-DCPG","volume":"528","author":"B\u00e4ckstr\u00f6m","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2022.173446_bb1025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s11689-015-9134-5","article-title":"Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study","volume":"8","author":"Bailey","year":"2016","journal-title":"J. Neurodev. Disord."},{"issue":"8","key":"10.1016\/j.pbb.2022.173446_bb1030","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/npp.2016.2","article-title":"An mGlu5-positive allosteric modulator rescues the neuroplasticity deficits in a genetic model of NMDA eeceptor hypofunction in schizophrenia","volume":"41","author":"Balu","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"20","key":"10.1016\/j.pbb.2022.173446_bb0040","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1523\/JNEUROSCI.0176-04.2004","article-title":"Preferential effects of the metabotropic glutamate 2\/3 receptor agonist LY379268 on conditioned reinstatement versus primary reinforcement: comparison between cocaine and a potent conventional reinforcer","volume":"24","author":"Baptista","year":"2004","journal-title":"J. Neurosci."},{"issue":"11","key":"10.1016\/j.pbb.2022.173446_bb0045","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.biopsych.2018.03.001","article-title":"Metabotropic glutamate receptor 5 as a target for the treatment of depression and smoking: robust preclinical data but inconclusive clinical efficacy","volume":"83","author":"Barnes","year":"2018","journal-title":"Biol Psychiatry"},{"issue":"1","key":"10.1016\/j.pbb.2022.173446_bb0050","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eplepsyres.2003.08.001","article-title":"Comparison of the effect of glutamate receptor modulators in the 6 hz and maximal electroshock seizure models","volume":"56","author":"Barton","year":"2003","journal-title":"Epilepsy Res."},{"issue":"27","key":"10.1016\/j.pbb.2022.173446_bb0055","doi-asserted-by":"crossref","first-page":"7222","DOI":"10.1523\/JNEUROSCI.1595-06.2006","article-title":"Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"26","author":"Battaglia","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2022.173446_bb1035","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.nbd.2014.11.012","article-title":"Activation of mGlu3 metabotropic glutamate receptors enhances GDNF and GLT-1 formation in the spinal cord and rescues motor neurons in the SOD-1 mouse model of amyotrophic lateral sclerosis","volume":"74","author":"Battaglia","year":"2015","journal-title":"Neurobiol. Dis."},{"issue":"6","key":"10.1016\/j.pbb.2022.173446_bb0060","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00004850-200511000-00001","article-title":"Metabotropic glutamate II receptor agonists in panic disorder: a double blind clinical trial with LY354740","volume":"20","author":"Bergink","year":"2005","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"321","key":"10.1016\/j.pbb.2022.173446_bb1040","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aab4109","article-title":"Mavoglurant in fragile X syndrome: results of two randomized, double-blind, placebo-controlled trials","volume":"8","author":"Berry-Kravis","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"Suppl 1","key":"10.1016\/j.pbb.2022.173446_bb1045","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.neuropharm.2005.06.007","article-title":"Metabotropic glutamate receptor (mGluR5) antagonist MPEP attenuated cue- and schedule-induced reinstatement of nicotine self-administration behavior in rats","volume":"49","author":"Bespalov","year":"2005","journal-title":"Neuropharmacology"},{"issue":"10","key":"10.1016\/j.pbb.2022.173446_bb0065","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1096\/fj.09-131789","article-title":"Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism","volume":"23","author":"Beurrier","year":"2009","journal-title":"FASEB J."},{"issue":"8","key":"10.1016\/j.pbb.2022.173446_bb1050","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/mds.25920","article-title":"The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model","volume":"29","author":"Bezard","year":"2014","journal-title":"Mov. Disord."},{"issue":"Pt A","key":"10.1016\/j.pbb.2022.173446_bb1060","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.nbd.2017.10.001","article-title":"Genetic inactivation of mGlu5 receptor improves motor coordination in the Grm1crv4\u202fmouse model of SCAR13 ataxia","volume":"109","author":"Bossi","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.pbb.2022.173446_bb1065","doi-asserted-by":"crossref","first-page":"108982","DOI":"10.1016\/j.neuropharm.2022.108982","article-title":"The comparative effects of mGlu5 receptor positive allosteric modulators VU0409551 and VU0360172 on cognitive deficits and signalling in the sub-chronic PCP rat model for schizophrenia","volume":"208","author":"Brown","year":"2022","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.pbb.2022.173446_bb1070","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1124\/mol.110.067488","volume":"79","author":"Caraci","year":"2011","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.pbb.2022.173446_bb1075","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1046\/j.1471-4159.2000.0751147.x","article-title":"The potent, selective mGlu2\/3 receptor agonist LY379268 increases extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindole-3-acetic acid in the medial prefrontal cortex of the freely moving rat","volume":"75","author":"Cartmell","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.pbb.2022.173446_bb1080","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.neuint.2019.03.020","article-title":"Metabotropic glutamate receptor 5 ablation accelerates age-related neurodegeneration and neuroinflammation","volume":"126","author":"Carvalho","year":"2019","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.pbb.2022.173446_bb1085","doi-asserted-by":"crossref","first-page":"107810","DOI":"10.1016\/j.neuropharm.2019.107810","article-title":"Neuroprotective effects of mGluR5 activation through the PI3K\/Akt pathway and the molecular switch of AMPA receptors","volume":"162","author":"Cavallo","year":"2020","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pbb.2022.173446_bb1090","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/j.pain.0000000000001695","article-title":"The metabotropic glutamate receptor 5 negative allosteric modulator fenobam: pharmacokinetics, side effects, and analgesic effects in healthy human subjects","volume":"161","author":"Cavallone","year":"2020","journal-title":"Pain"},{"issue":"4","key":"10.1016\/j.pbb.2022.173446_bb1095","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.pbb.2012.12.008","article-title":"Positive allosteric modulation of mGlu7 receptors by AMN082 affects sleep and wakefulness in the rat","volume":"103","author":"Cavas","year":"2013","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"6","key":"10.1016\/j.pbb.2022.173446_bb1105","first-page":"747","article-title":"Targeting ionotropic glutamate receptors in the treatment of epilepsy","volume":"19","author":"Celli","year":"2021","journal-title":"Curr. Neuropharmacol."},{"issue":"4","key":"10.1016\/j.pbb.2022.173446_bb1100","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/14728222.2019.1586885","article-title":"Targeting metabotropic glutamate receptors in the treatment of epilepsy: rationale and current status","volume":"23","author":"Celli","year":"2019","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.pbb.2022.173446_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172995","article-title":"Recent advances in the antidepressant actions of ketamine and agents having ketamine-like antidepressant profiles","volume":"196","author":"Chaki","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"2","key":"10.1016\/j.pbb.2022.173446_bb1110","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2174\/138161211795049570","article-title":"Targeting of metabotropic glutamate receptors for the treatment of schizophrenia","volume":"17","author":"Chaki","year":"2011","journal-title":"Curr. Pharm. Design"},{"issue":"10","key":"10.1016\/j.pbb.2022.173446_bb1115","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1002\/mds.27462","article-title":"An mGlu4-positive allosteric modulator alleviates parkinsonism in primates","volume":"33","author":"Charvin","year":"2018","journal-title":"Mov. Disord.: Off. J. Mov. Disord. Soc."},{"issue":"4","key":"10.1016\/j.pbb.2022.173446_bb0080","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.neuropharm.2003.10.009","article-title":"MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity","volume":"46","author":"Chaki","year":"2004","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pbb.2022.173446_bb1120","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.coph.2011.10.010","article-title":"Metabotropic glutamate receptors and the control of chronic pain","volume":"12","author":"Chiechio","year":"2012","journal-title":"Curr. Opin. Pharmacol."},{"issue":"5","key":"10.1016\/j.pbb.2022.173446_bb1125","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1124\/mol.108.054346","article-title":"Epigenetic modulation of mGlu2 receptors by histone deacetylase inhibitors in the treatment of inflammatory pain","volume":"75","author":"Chiechio","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.pbb.2022.173446_bb1130","doi-asserted-by":"crossref","first-page":"107866","DOI":"10.1016\/j.neuropharm.2019.107866","article-title":"Simultaneous activation of mGlu2\u202fand muscarinic receptors reverses MK-801-induced cognitive decline in rodents","volume":"174","author":"Cie\u015blik","year":"2020","journal-title":"Neuropharmacology"},{"issue":"11","key":"10.1016\/j.pbb.2022.173446_bb0095","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.3389\/fphar.2020.01108","article-title":"Acute low dose of trazodone recovers glutamate release efficiency and mGlu2\/3 autoreceptor impairments in the spinal cord of rats suffering from chronic sciatic ligation","volume":"17","author":"Cisani","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.pbb.2022.173446_bb1135","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1146\/annurev.pharmtox.37.1.205","article-title":"Pharmacology and functions of metabotropic glutamate receptors","volume":"37","author":"Conn","year":"1997","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"8","key":"10.1016\/j.pbb.2022.173446_bb0100","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/bph.15640","article-title":"Group II metabotropic glutamate receptor (mGlu2 and mGlu3) roles in thalamic processing","volume":"179","author":"Copeland","year":"2021","journal-title":"Br J Pharmacol."},{"issue":"5","key":"10.1016\/j.pbb.2022.173446_bb1140","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/cts.12566","article-title":"Population pharmacokinetic and exposure-dizziness modeling for a metabotropic glutamate receptor subtype 5 negative allosteric modulator in major depressive disorder patients","volume":"11","author":"Cosson","year":"2018","journal-title":"Clin. Trans. Sci."},{"issue":"11","key":"10.1016\/j.pbb.2022.173446_bb1145","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1038\/s41386-020-0708-x","article-title":"mGlu5 receptor availability in youth at risk for addictions: effects of vulnerability traits and cannabis use","volume":"45","author":"Cox","year":"2020","journal-title":"Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.pbb.2022.173446_bb0105","first-page":"97","article-title":"Amino acid transmitters in the mammalian central nervous system","volume":"69","author":"Curtis","year":"1974","journal-title":"Ergeb Physiol."},{"issue":"3","key":"10.1016\/j.pbb.2022.173446_bb0110","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00109-020-01982-z","article-title":"Memantine in neurological disorders - schizophrenia and depression","volume":"99","author":"Czarnecka","year":"2021","journal-title":"J. Mol. Med. (Berl)"},{"issue":"7","key":"10.1016\/j.pbb.2022.173446_bb1150","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/epi.13024","article-title":"Anti-absence activity of mGlu1 and mGlu5 receptor enhancers and their interaction with a GABA reuptake inhibitor: Effect of local infusions in the somatosensory cortex and thalamus","volume":"56","author":"D'Amore","year":"2015","journal-title":"Epilepsia."},{"key":"10.1016\/j.pbb.2022.173446_bb1155","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pbb.2016.05.004","article-title":"The anti-absence effect of mGlu5 receptor amplification with VU0360172 is maintained during and after antiepileptogenesis","volume":"146-147","author":"D'Amore","year":"2016","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"9","key":"10.1016\/j.pbb.2022.173446_bb1160","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1097\/j.pain.0000000000000621","article-title":"Group II mGluRs suppress hyperexcitability in mouse and human nociceptors","volume":"157","author":"Davidson","year":"2016","journal-title":"Pain"},{"key":"10.1016\/j.pbb.2022.173446_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127724","article-title":"Lead optimization of the VU0486321 series of mGlu1 PAMs. Part 4: SAR reveals positive cooperativity across multiple mGlu receptor subtypes leading to subtype unselective PAMs","volume":"32","author":"Davis","year":"2021","journal-title":"Bioorg Med Chem Lett."},{"issue":"3","key":"10.1016\/j.pbb.2022.173446_bb1165","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.biopsych.2014.06.024","article-title":"In vivo ketamine-induced changes in [\u00b9\u00b9C]ABP688 binding to metabotropic glutamate receptor subtype 5","volume":"77","author":"DeLorenzo","year":"2015","journal-title":"Biol. Psychiatry"},{"issue":"12","key":"10.1016\/j.pbb.2022.173446_bb1170","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.189","article-title":"Characterization of brain mGluR5 binding in a pilot study of late-life major depressive disorder using positron emission tomography and [\u00b9\u00b9C]ABP688","volume":"5","author":"DeLorenzo","year":"2015","journal-title":"Transl. Psychiatry"},{"issue":"7","key":"10.1016\/j.pbb.2022.173446_bb1175","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1176\/appi.ajp.2011.09111607","article-title":"Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study","volume":"168","author":"Deschwanden","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pbb.2022.173446_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2020.135603","article-title":"LSP2-9166, an orthosteric mGlu4 and mGlu7 receptor agonist, reduces cocaine self-administration under a progressive ratio schedule in rats","volume":"764","author":"De Sa Nogueira","year":"2021","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.pbb.2022.173446_bb1180","doi-asserted-by":"crossref","first-page":"105338","DOI":"10.1016\/j.nbd.2021.105338","article-title":"Fragile X mental retardation protein (FMRP) and metabotropic glutamate receptor subtype 5 (mGlu5) control stress granule formation in astrocytes","volume":"154","author":"Di Marco","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.pbb.2022.173446_bb1185","doi-asserted-by":"crossref","first-page":"108687","DOI":"10.1016\/j.neuropharm.2021.108687","article-title":"Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders","volume":"196","author":"Dogra","year":"2021","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.pbb.2022.173446_bb0130","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1124\/molpharm.121.000460","article-title":"Metabotropic glutamate receptors as emerging targets for the treatment of schizophrenia","volume":"101","author":"Dogra","year":"2022","journal-title":"Mol. Pharmacol."},{"issue":"7","key":"10.1016\/j.pbb.2022.173446_bb0140","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/FBP.0b013e32832ec5d1","article-title":"The selective metabotropic glutamate receptor 7 allosteric agonist AMN082 inhibits inflammatory pain-induced and incision-induced hypersensitivity in rat","volume":"20","author":"Dolan","year":"2009","journal-title":"Behav. Pharmacol."},{"issue":"12","key":"10.1016\/j.pbb.2022.173446_bb0145","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1080\/13543784.2020.1839047","article-title":"A case study of foliglurax, the first clinical mGluR4 PAM for symptomatic treatment of Parkinson's disease: translational gaps or a failing industry innovation model?","volume":"29","author":"Doller","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.pbb.2022.173446_bb1190","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.neuint.2014.12.010","article-title":"Neuroprotective effects of the allosteric agonist of metabotropic glutamate receptor 7 AMN082 on oxygen-glucose deprivation- and kainate-induced neuronal cell death","volume":"88","author":"Domin","year":"2015","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.pbb.2022.173446_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2021.173316","article-title":"Antidepressant-like actions of the mGlu2\/3 receptor antagonist TP0178894 in the chronic social defeat stress model: comparison with escitalopram","volume":"212","author":"Dong","year":"2022","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"14","key":"10.1016\/j.pbb.2022.173446_bb0155","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/s12888-014-0351-3","article-title":"A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia","volume":"10","author":"Downing","year":"2014","journal-title":"BMC Psychiatry."},{"issue":"11","key":"10.1016\/j.pbb.2022.173446_bb1195","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1093\/cercor\/bhw249","article-title":"Metabotropic glutamate receptor type 5 (mglur5) cortical abnormalities in focal cortical dysplasia identified in vivo with [11c]abp688 positron-emission tomography (PET) imaging","volume":"26","author":"DuBois","year":"2016","journal-title":"Cerebral Cortex (New York, N.Y. : 1991)"},{"issue":"7","key":"10.1016\/j.pbb.2022.173446_bb0160","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1038\/sj.npp.1301531","article-title":"Efficacy and tolerability of an mGlu2\/3 agonist in the treatment of generalized anxiety disorder","volume":"33","author":"Dunayevich","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"18","key":"10.1016\/j.pbb.2022.173446_bb0165","doi-asserted-by":"crossref","first-page":"7485","DOI":"10.1021\/acs.jmedchem.5b01005","article-title":"Discovery of a selective and CNS penetrant negative allosteric modulator of metabotropic glutamate receptor subtype 3 with antidepressant and anxiolytic activity in rodents","volume":"58","author":"Engers","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pbb.2022.173446_bb1205","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.brainres.2008.05.073","article-title":"Differential changes in mGlu2 and mGlu3 gene expression following pilocarpine-induced status epilepticus: a comparative real-time PCR analysis","volume":"1226","author":"Ermolinsky","year":"2008","journal-title":"Brain Res."},{"issue":"4","key":"10.1016\/j.pbb.2022.173446_bb1200","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/mp.2017.58","article-title":"Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression","volume":"23","author":"Esterlis","year":"2018","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pbb.2022.173446_bb1210","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/jpet.108.136861","article-title":"Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2\/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J","volume":"326","author":"Fell","year":"2008","journal-title":"Pharm. Exp. Ther."},{"issue":"1","key":"10.1016\/j.pbb.2022.173446_bb0170","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1124\/jpet.110.172957","volume":"336","author":"Fell","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.pbb.2022.173446_bb1215","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1124\/jpet.104.076547","volume":"312","author":"Feinberg","year":"2005","journal-title":"J. Phar. Exp. Ther."},{"issue":"6","key":"10.1016\/j.pbb.2022.173446_bb1220","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/1440-1681.12410","article-title":"Selective blockade of mGlu5 metabotropic glutamate receptors is protective against hepatic mitochondrial dysfunction in 6-OHDA lesioned Parkinsonian rats","volume":"2","author":"Ferrigno","year":"2015","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"4","key":"10.1016\/j.pbb.2022.173446_bb1225","article-title":"A GRM7 mutation associated with developmental delay reduces mGlu7 expression and produces neurological phenotypes","volume":"6","author":"Fisher","year":"2021","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.pbb.2022.173446_bb0175","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1124\/jpet.107.131417","article-title":"Morphine in combination with metabotropic glutamate receptor antagonists on schedule-controlled responding and thermal nociception","volume":"324","author":"Fischer","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.pbb.2022.173446_bb1230","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00702-020-02287-8","article-title":"Effect of the mGlu2\u202fpositive allosteric modulator CBiPES on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset","volume":"128","author":"Frouni","year":"2021","journal-title":"J. Neural Trans. (Vienna, Austria : 1996)"},{"key":"10.1016\/j.pbb.2022.173446_bb0180","first-page":"20","article-title":"Safety, pharmacokinetic and pharmacodynamic profile of BCI-632, a selective metabotropic glutamate 2\/3 receptor antagonist, in healthy human subjects","volume":"841","author":"Gadient","year":"2012","journal-title":"Poster"},{"key":"10.1016\/j.pbb.2022.173446_bb1235","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.bbr.2012.10.059","article-title":"Chronic administration of AFQ056\/Mavoglurant restores social behaviour in Fmr1 knockout mice","volume":"239","author":"Gantois","year":"2013","journal-title":"Behav. Brain Res."},{"issue":"12","key":"10.1016\/j.pbb.2022.173446_bb1240","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1177\/0269881117715597","article-title":"A group II metabotropic glutamate receptor 3 (mGlu3, GRM3) isoform implicated in schizophrenia interacts with canonical mGlu3 and reduces ligand binding","volume":"31","author":"Garc\u00eda-Bea","year":"2017","journal-title":"J. Psychopharm. (Oxford, England)"},{"issue":"16","key":"10.1016\/j.pbb.2022.173446_bb1245","doi-asserted-by":"crossref","first-page":"10975","DOI":"10.1074\/jbc.M113.542654","article-title":"Blocking metabotropic glutamate receptor subtype 7 (mGlu7) via the Venus flytrap domain (VFTD) inhibits amygdala plasticity, stress, and anxiety-related behavior","volume":"289","author":"Gee","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pbb.2022.173446_bb1250","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.neuropharm.2012.07.030","article-title":"In vitro characterisation of the novel positive allosteric modulators of the mGlu\u2085 receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat","volume":"64","author":"Gilmour","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2022.173446_bb1255","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2019.04.016","article-title":"The mGlu7 receptor provides protective effects against epileptogenesis and epileptic seizures","volume":"129","author":"Girard","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.pbb.2022.173446_bb1275","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neuropharm.2012.08.001","article-title":"Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target","volume":"64","author":"Goeldner","year":"2013","journal-title":"Neuropharmacology"},{"issue":"403","key":"10.1016\/j.pbb.2022.173446_bb1260","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aai7459","article-title":"mGlu7\u202fpotentiation rescues cognitive, social, and respiratory phenotypes in a mouse model of Rett syndrome","volume":"9","author":"Gogliotti","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.pbb.2022.173446_bb1265","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1093\/hmg\/ddw074","article-title":"mGlu5 positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndrome","volume":"25","author":"Gogliotti","year":"2016","journal-title":"Hum. Mol. Genet."},{"issue":"4","key":"10.1016\/j.pbb.2022.173446_bb1270","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/npp.2015.265","article-title":"Partial mGlu\u2085 negative allosteric modulators attenuate cocaine-mediated behaviors and lack psychotomimetic-like effects","volume":"41","author":"Gould","year":"2016","journal-title":"Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.pbb.2022.173446_bb2280","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.pain.2007.08.020","article-title":"Group III metabotropic glutamate receptors inhibit hyperalgesia in animal models of inflammation and neuropathic pain","volume":"137","author":"Goudet","year":"2008","journal-title":"Pain"},{"issue":"4","key":"10.1016\/j.pbb.2022.173446_bb0185","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1471-4159.1967.tb09545.x","article-title":"Distribution of some synaptic transmitter suspects in cat spinal cord: glutamic acid, aspartic acid, gamma-aminobutyric acid, glycine and glutamine","volume":"14","author":"Graham","year":"1967","journal-title":"J. Neurochem."},{"issue":"3","key":"10.1016\/j.pbb.2022.173446_bb0190","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1124\/jpet.109.162115","article-title":"Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease","volume":"332","author":"Greco","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2022.173446_bb1285","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.dib.2017.09.018","article-title":"Dataset for Phase I randomized clinical trial for safety and tolerability of GET 73 in single and repeated ascending doses including preliminary pharmacokinetic parameters","volume":"15","author":"Haass-Koffler","year":"2017","journal-title":"Data Brief"},{"issue":"1","key":"10.1016\/j.pbb.2022.173446_bb1290","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00213-021-06008-1","article-title":"An inpatient human laboratory study assessing the safety and tolerability, pharmacokinetics, and biobehavioral effect of GET 73 when co-administered with alcohol in individuals with alcohol use disorder","volume":"239","author":"Haass-Koffler","year":"2022","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2022.173446_bb1295","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.neuropharm.2018.01.002","article-title":"Role of mGlu7 receptor in morphine rewarding effects is uncovered by a novel orthosteric agonist","volume":"131","author":"Hajasova","year":"2018","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.pbb.2022.173446_bb1300","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsz123","article-title":"Pharmacological Modulation of Sleep Homeostasis in Rat: Novel Effects of an mGluR2\/3 Antagonist","volume":"42","author":"Hanley","year":"2019","journal-title":"Sleep"},{"key":"10.1016\/j.pbb.2022.173446_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114892","article-title":"Mechanisms of ketamine and its metabolites as antidepressants","volume":"197","author":"Hess","year":"2022","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.pbb.2022.173446_bb1305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0209984","article-title":"Effects of mavoglurant on visual attention and pupil reactivity while viewing photographs of faces in Fragile X Syndrome","volume":"14","author":"Hessl","year":"2019","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.pbb.2022.173446_bb1310","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.neuropharm.2004.01.018","article-title":"Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent","volume":"46","author":"Higgins","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2022.173446_bb1315","doi-asserted-by":"crossref","first-page":"700822","DOI":"10.3389\/fnins.2021.700822","article-title":"Partial mGlu5\u202fnegative allosteric modulator m-5mpep demonstrates antidepressant-like effects on sleep without affecting cognition or quantitative eeg","volume":"15","author":"Holter","year":"2021","journal-title":"Front. Neurosci."},{"issue":"2","key":"10.1016\/j.pbb.2022.173446_bb1320","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.neuron.2019.07.011","article-title":"Enhanced mGlu5 signaling in excitatory neurons promotes rapid antidepressant effects via ampa receptor activation","volume":"104","author":"Holz","year":"2019","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.pbb.2022.173446_bb0200","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1021\/cn400023y","article-title":"Is there a path forward for mGlu(2) positive allosteric modulators for the treatment of schizophrenia?","volume":"4","author":"Hopkins","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.pbb.2022.173446_bb0205","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jad.2022.03.047","article-title":"The efficacy and tolerability of memantine for depressive symptoms in major mental diseases: a systematic review and updated meta-analysis of double-blind randomized controlled trials","volume":"306","author":"Hsu","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.pbb.2022.173446_bb1325","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coph.2018.02.005","article-title":"Targeting metabotropic glutamate receptors in the treatment of primary brain tumors","volume":"38","author":"Iacovelli","year":"2018","journal-title":"Curr. Opinion Pharm."},{"issue":"2","key":"10.1016\/j.pbb.2022.173446_bb0210","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00213-006-0618-6","article-title":"Effects of metabotropic glutamate 2\/3 receptor antagonists in the stress-induced hyperthermia test in singly housed mice","volume":"190","author":"Iijima","year":"2007","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.pbb.2022.173446_bb0215","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1527-3458.2007.00024.x","article-title":"The preclinical properties of a novel group II metabotropic glutamate receptor agonist LY379268","volume":"13","author":"Imre","year":"2007","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.pbb.2022.173446_bb0220","first-page":"1","article-title":"The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis","author":"Jawad","year":"2022","journal-title":"Expert opinion on drug safety"},{"issue":"1","key":"10.1016\/j.pbb.2022.173446_bb1335","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s13023-021-01951-w","article-title":"A large consanguineous family with a homozygous Metabotropic Glutamate Receptor 7 (mGlu7) variant and developmental epileptic encephalopathy: effect on protein structure and ligand affinity","volume":"16","author":"Jdila","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"issue":"1-2","key":"10.1016\/j.pbb.2022.173446_bb1330","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejphar.2005.07.007","article-title":"Transient lower esophageal sphincter relaxations in dogs are inhibited by a metabotropic glutamate receptor 5 antagonist","volume":"519","author":"Jensen","year":"2005","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.pbb.2022.173446_bb1340","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.neuron.2021.12.027","article-title":"Acute restraint stress redirects prefrontal cortex circuit function through mGlu5\u202freceptor plasticity on somatostatin-expressing interneurons","volume":"110","author":"Joffe","year":"2022","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.pbb.2022.173446_bb0225","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.neuron.2019.09.044","article-title":"mGlu2 and mGlu3 negative allosteric modulators divergently enhance thalamocortical transmission and exert rapid antidepressant-like effects","volume":"105","author":"Joffe","year":"2020","journal-title":"Neuron"},{"issue":"Suppl. 1","key":"10.1016\/j.pbb.2022.173446_bb0235","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.neuropharm.2005.05.008","article-title":"Analgesic effects of the selective group II (mGlu2\/3) metabotropic glutamate receptor agonists LY379268 and LY389795 in persistent and inflammatory pain models after acute and repeated dosing","volume":"49","author":"Jones","year":"2005","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.1016\/j.pbb.2022.173446_bb0240","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.biopsych.2015.01.014","article-title":"The novel metabotropic glutamate receptor 2 positive allosteric modulator, AZD8529, decreases nicotine self-administration and relapse in squirrel monkeys","volume":"78","author":"Justinova","year":"2015","journal-title":"Biol Psychiatry"},{"issue":"11","key":"10.1016\/j.pbb.2022.173446_bb0245","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1038\/s41386-020-0706-z","article-title":"Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers","volume":"45","author":"Kantrowitz","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.pbb.2022.173446_bb1345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12993-021-00174-0","article-title":"The effect of the mGlu8 receptor agonist, (S)-3,4-DCPG on acquisition and expression of morphine-induced conditioned place preference in male rats","volume":"17","author":"Kahvandi","year":"2021","journal-title":"Behav. Brain Functions : BBF"},{"issue":"3","key":"10.1016\/j.pbb.2022.173446_bb1350","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1124\/jpet.112.200915","article-title":"ADX71743, a potent and selective negative allosteric modulator of metabotropic glutamate receptor 7: in vitro and in vivo characterization","volume":"344","author":"Kalinichev","year":"2013","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.pbb.2022.173446_bb0250","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.pnpbp.2016.01.009","article-title":"Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI\/SNRI in anxious depression","volume":"67","author":"Kent","year":"2016","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.pbb.2022.173446_bb1370","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1124\/jpet.103.052027","article-title":"Group II metabotropic and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)\/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats","volume":"306","author":"Kenny","year":"2003","journal-title":"J. Pharm. Exp. Ther."},{"issue":"9","key":"10.1016\/j.pbb.2022.173446_bb1355","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1136\/gut.2008.162040","article-title":"A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease","volume":"58","author":"Keywood","year":"2009","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.pbb.2022.173446_bb1375","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/mp.2014.87","article-title":"Proneurogenic Group II mGluR antagonist improves learning and reduces anxiety in Alzheimer A\u03b2 oligomer mouse","volume":"19","author":"Kim","year":"2014","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pbb.2022.173446_bb0255","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.neuropharm.2012.06.002","article-title":"Clinical development of pomaglumetad methionil: a non-dopaminergic treatment for schizophrenia","volume":"66","author":"Kinon","year":"2013","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.pbb.2022.173446_bb0260","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/JCP.0b013e318218dcd5","article-title":"A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia","volume":"31","author":"Kinon","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.pbb.2022.173446_bb0265","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.biopsych.2015.03.016","article-title":"Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2\/3 receptor agonist pomaglumetad methionil in schizophrenia","volume":"78","author":"Kinon","year":"2015","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.pbb.2022.173446_bb0270","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00726-006-0316-z","article-title":"Combined administration of PHCCC, a positive allosteric modulator of mGlu4 receptors and ACPT-I, mGlu III receptor agonist evokes antidepressant-like effects in rats","volume":"32","author":"K\u0142ak","year":"2007","journal-title":"Amino Acids"},{"issue":"19","key":"10.1016\/j.pbb.2022.173446_bb1360","doi-asserted-by":"crossref","first-page":"7600","DOI":"10.1523\/JNEUROSCI.4543-14.2015","article-title":"Activation of Metabotropic Glutamate Receptor 7 is required for induction of long-term potentiation at SC-CA1 synapses in the hippocampus","volume":"35","author":"Klar","year":"2015","journal-title":"J. Neuro. : Off. J. Soc. Neurosci."},{"issue":"1 Pt 1","key":"10.1016\/j.pbb.2022.173446_bb1365","first-page":"113","article-title":"The anxiolytic-like activity of AIDA (1-aminoindan-1,5-dicarboxylic acid), an mGLu 1 receptor antagonist","volume":"55","author":"K\u0142odzi\u0144ska","year":"2004","journal-title":"J. Physiol. Pharmacol."},{"issue":"5267","key":"10.1016\/j.pbb.2022.173446_bb0275","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/228119a0","article-title":"Glutamate and gamma-aminobutyric acid in brain","volume":"228","author":"Krnjevi\u0107","year":"1970","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pbb.2022.173446_bb1380","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3109\/00207454.2013.841685","article-title":"Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients","volume":"126","author":"Kumar","year":"2016","journal-title":"Int. J. Neuro."},{"issue":"9","key":"10.1016\/j.pbb.2022.173446_bb1385","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.3389\/fphar.2018.01306","article-title":"mGlu5 receptor blockade within the nucleus accumbens shell reduces behavioral indices of alcohol withdrawal-induced anxiety in mice","volume":"2018","author":"Lee","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.pbb.2022.173446_bb1390","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.nbd.2011.01.022","article-title":"AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome","volume":"42","author":"Levenga","year":"2011","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.pbb.2022.173446_bb1395","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1124\/jpet.106.103143","article-title":"Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice","volume":"319","author":"Li","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.pbb.2022.173446_bb0285","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0028-3908(03)00200-4","article-title":"Systemic administration of the potent mGlu8 receptor agonist (S)-3,4-DCPG induces c-fos in stress-related brain regions in wild-type, but not mGlu8 receptor knockout mice","volume":"45","author":"Linden","year":"2003","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pbb.2022.173446_bb0290","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s00213-004-2098-x","article-title":"Anxiolytic-like activity of the mGLU2\/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice","volume":"179","author":"Linden","year":"2005","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.pbb.2022.173446_bb1400","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1124\/jpet.114.222463","article-title":"Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression","volume":"353","author":"Lindemann","year":"2015","journal-title":"J. Pharm. Exp. Ther."},{"issue":"1\u20133","key":"10.1016\/j.pbb.2022.173446_bb0295","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.schres.2016.02.001","article-title":"AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: a proof of principle study","volume":"172","author":"Litman","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pbb.2022.173446_bb1405","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/978-1-4939-9121-1_20","article-title":"Optical modulation of metabotropic glutamate receptor type 5 in vivo using a photoactive drug","volume":"1947","author":"L\u00f3pez-Cano","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.pbb.2022.173446_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2022.106895","article-title":"Efficacy, tolerability and safety of perampanel in population with pharmacoresistant focal seizures: A systematic review and meta-analysis","volume":"182","author":"Mahajan","year":"2022","journal-title":"Epilepsy research"},{"issue":"5","key":"10.1016\/j.pbb.2022.173446_bb1410","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109950","article-title":"mGlu1\u202fpotentiation enhances prelimbic somatostatin interneuron activity to rescue schizophrenia-like physiological and cognitive deficits","volume":"37","author":"Maksymetz","year":"2021","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.pbb.2022.173446_bb1415","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13041-017-0293-z","article-title":"Targeting metabotropic glutamate receptors for novel treatments of schizophrenia","volume":"10","author":"Maksymetz","year":"2017","journal-title":"Mol. Brain"},{"issue":"2","key":"10.1016\/j.pbb.2022.173446_bb1425","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.neuropharm.2006.04.006","article-title":"Effects of (S)-3,4-DCPG, an mGlu8 receptor agonist, on inflammatory and neuropathic pain in mice","volume":"52","author":"Marabese","year":"2007","journal-title":"Neuropharmacology"},{"issue":"26","key":"10.1016\/j.pbb.2022.173446_bb0310","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.2174\/1381612821666150605105632","article-title":"When is a proof-of-concept (POC) not a POC? Pomaglumetad (LY2140023) as a case study for antipsychotic efficacy","volume":"21","author":"Marek","year":"2015","journal-title":"Curr. Pharm. Des."},{"issue":"3","key":"10.1016\/j.pbb.2022.173446_bb1430","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s12640-017-9857-z","article-title":"Effects of the positive allosteric modulator of metabotropic glutamate receptor 5, vu-29, on impairment of novel object recognition induced by acute ethanol and ethanol withdrawal in rats","volume":"33","author":"Marszalek-Grabska","year":"2018","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.pbb.2022.173446_bb1435","doi-asserted-by":"crossref","first-page":"108608","DOI":"10.1016\/j.neuropharm.2021.108608","article-title":"Rescue of striatal long-term depression by chronic mGlu5 receptor negative allosteric modulation in distinct dystonia models","volume":"192","author":"Martella","year":"2021","journal-title":"Neuropharmacology"},{"issue":"11","key":"10.1016\/j.pbb.2022.173446_bb1440","doi-asserted-by":"crossref","first-page":"5867","DOI":"10.3390\/ijms22115867","article-title":"the density of group i mglu5\u202freceptors is reduced along the neuronal surface of hippocampal cells in a mouse model of alzheimer's disease","volume":"22","author":"Mart\u00edn-Belmonte","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pbb.2022.173446_bb1445","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jpsychires.2020.04.005","article-title":"The positive allosteric modulator of the mGlu2 receptor JNJ-46356479 partially improves neuropathological deficits and schizophrenia-like behaviors in a postnatal ketamine mice model","volume":"126","author":"Mart\u00ednez-Pinte\u00f1o","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pbb.2022.173446_bb1450","doi-asserted-by":"crossref","first-page":"668877","DOI":"10.3389\/fneur.2021.668877","article-title":"Genetic deletion of mGlu3 metabotropic glutamate receptors amplifies ischemic brain damage and associated neuroinflammation in mice","volume":"12","author":"Mastroiacovo","year":"2021","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.pbb.2022.173446_bb1465","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.neuropharm.2007.10.020","article-title":"Synergism between fluoxetine and the mGlu2\/3 receptor agonist, LY379268, in an in vitro model for antidepressant drug-induced neurogenesis","volume":"54","author":"Matrisciano","year":"2008","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pbb.2022.173446_bb1460","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/1570159X13666150713174242","article-title":"Metabotropic glutamate 2\/3 receptors and epigenetic modifications in psychotic disorders: a review","volume":"14","author":"Matrisciano","year":"2016","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.pbb.2022.173446_bb1455","doi-asserted-by":"crossref","DOI":"10.2174\/1567202619999220209112609","article-title":"Altered expression and in vivo activity of mglu5 variant a receptors in the striatum of BTBR mice: novel insights into the pathophysiology of adult idiopathic forms of autism spectrum disorders [published online ahead of print, 2022 Feb 9]","author":"Matrisciano","year":"2022","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.pbb.2022.173446_bb0315","doi-asserted-by":"crossref","unstructured":"McColm et al., 2017J McColm C Brittain S Suriyapperuma S Swanson S Tauscher-Wisniewski J Foster D Soon K Jackson. Evaluation of single and multiple doses of a novel mGlu2 agonist, a potential antipsychotic therapy, in healthy subjects. Br. J. Clin. Pharmacol. 2017 Aug;83(8):1654-1667. doi:10.1111\/bcp.13252. Epub 2017 Mar 31. PMID: 28156011; PMCID: PMC5510079.","DOI":"10.1111\/bcp.13252"},{"issue":"7","key":"10.1016\/j.pbb.2022.173446_bb0320","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s00213-018-4877-9","article-title":"Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjects","volume":"235","author":"Mehta","year":"2018","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.pbb.2022.173446_bb1470","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/epi.14005","article-title":"Potent and selective pharmacodynamic synergy between the metabotropic glutamate receptor subtype 2-positive allosteric modulator JNJ-46356479 and levetiracetam in the mouse 6-Hz (44-mA) model","volume":"59","author":"Metcalf","year":"2018","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.pbb.2022.173446_bb1475","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuron.2012.03.009","article-title":"Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice","volume":"74","author":"Michalon","year":"2012","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.pbb.2022.173446_bb1480","doi-asserted-by":"crossref","first-page":"6374","DOI":"10.1038\/s41598-020-63389-7","article-title":"Metabotropic glutamate receptor 5 in bulimia nervosa","volume":"10","author":"Mihov","year":"2020","journal-title":"Sci. Rep."},{"issue":"18","key":"10.1016\/j.pbb.2022.173446_bb1485","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1111\/bph.15515","article-title":"Blocking glutamate mGlu5\u202freceptors with the negative allosteric modulator CTEP improves disease course in SOD1G93A\u202fmouse model of amyotrophic lateral sclerosis","volume":"178","author":"Milanese","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2022.173446_bb1490","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.neuroimage.2014.04.061","article-title":"Limbic system mGluR5 availability in cocaine dependent subjects: a high-resolution PET [(11)C]ABP688 study","volume":"98","author":"Milella","year":"2014","journal-title":"NeuroImage"},{"issue":"1","key":"10.1016\/j.pbb.2022.173446_bb0325","doi-asserted-by":"crossref","first-page":"15897","DOI":"10.1038\/s41598-021-94967-y","article-title":"In vivo imaging of mGlu5 receptor expression in humans with fragile X syndrome towards development of a potential biomarker","volume":"11","author":"Mody","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pbb.2022.173446_bb1420","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ynstr.2015.04.001","article-title":"Negative allosteric modulation of the mGlu7 receptor reduces visceral hypersensitivity in a stress-sensitive rat strain","volume":"2","author":"Moloney","year":"2015","journal-title":"Neurobiol. Stress"},{"issue":"3","key":"10.1016\/j.pbb.2022.173446_bb1495","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1124\/jpet.109.154138","article-title":"The metabotropic glutamate receptor subtype 5 antagonist fenobam is analgesic and has improved in vivo selectivity compared with the prototypical antagonist 2-methyl-6-(phenylethynyl)-pyridine","volume":"330","author":"Montana","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.pbb.2022.173446_bb0330","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/17460441.2019.1567487","article-title":"Successes, failures, and future prospects of prodrugs and their clinical impact","volume":"14","author":"Najjar","year":"2019","journal-title":"Expert Opin. Drug Discovery"},{"key":"10.1016\/j.pbb.2022.173446_bb0335","doi-asserted-by":"crossref","first-page":"4804","DOI":"10.1073\/pnas.1216100110","article-title":"L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors","volume":"110","author":"Nasca","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.pbb.2022.173446_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109648","article-title":"Agonists and allosteric modulators promote signaling from different metabotropic glutamate receptor 5 conformations","volume":"36","author":"Nasrallah","year":"2021","journal-title":"Cell Rep."},{"issue":"8","key":"10.1016\/j.pbb.2022.173446_bb1500","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1007\/s10072-021-05319-7","article-title":"Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease: a meta-analysis","volume":"42","author":"Negida","year":"2021","journal-title":"Neurol. Sci.: Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol."},{"issue":"7","key":"10.1016\/j.pbb.2022.173446_bb1505","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0166-2236(96)20019-0","article-title":"Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders?","volume":"19","author":"Nicoletti","year":"1996","journal-title":"Trends Neurosci."},{"issue":"1","key":"10.1016\/j.pbb.2022.173446_bb1510","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/jpm6010009","article-title":"Serotonin 2A receptor SNP rs7330461 association with treatment response to pomaglumetad methionil in patients with schizophrenia","volume":"6","author":"Nisenbaum","year":"2016","journal-title":"J. Personalized Med."},{"key":"10.1016\/j.pbb.2022.173446_bb1525","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.coph.2018.01.012","article-title":"Metabotropic glutamate receptors as drug targets for the treatment of absence epilepsy","volume":"38","author":"Ngomba","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.pbb.2022.173446_bb1520","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.neuropharm.2005.05.019","article-title":"The preferential mGlu2\/3 receptor antagonist, LY341495, reduces the frequency of spike-wave discharges in the WAG\/Rij rat model of absence epilepsy","volume":"49","author":"Ngomba","year":"2005","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.pbb.2022.173446_bb1515","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.neuropharm.2007.10.004","article-title":"Positive allosteric modulation of metabotropic glutamate 4 (mGlu4) receptors enhances spontaneous and evoked absence seizures","volume":"54","author":"Ngomba","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2022.173446_bb0350","doi-asserted-by":"crossref","DOI":"10.1177\/1744806920904292","article-title":"N-acetylcysteine causes analgesia in a mouse model of painful diabetic neuropathy","volume":"16","author":"Notartomaso","year":"2020","journal-title":"Mol. Pain"},{"key":"10.1016\/j.pbb.2022.173446_bb1530","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.neuropharm.2014.04.016","article-title":"Prolonged administration of antidepressant drugs leads to increased binding of [(3)H]MPEP to mGlu5 receptors","volume":"84","author":"Nowak","year":"2014","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.pbb.2022.173446_bb1535","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/FBP.0b013e32835efc78","article-title":"The effects of mGlu\u2087 receptor modulation in behavioural models sensitive to antidepressant action in two mouse strains","volume":"24","author":"O'Connor","year":"2013","journal-title":"Behav. Pharmacol."},{"issue":"4","key":"10.1016\/j.pbb.2022.173446_bb0355","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00213-007-0856-2","article-title":"Activation of the mGlu7 receptor elicits antidepressant-like effects in mice","volume":"194","author":"Palucha","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2022.173446_bb1540","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bbr.2012.10.004","article-title":"A selective mGlu7 receptor antagonist MMPIP reversed antidepressant-like effects of AMN082 in rats","volume":"238","author":"Pa\u0142ucha-Poniewiera","year":"2013","journal-title":"Behav. Brain Res."},{"issue":"6","key":"10.1016\/j.pbb.2022.173446_bb1545","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S1734-1140(13)71511-1","article-title":"Is the mGlu5 receptor a possible target for new antidepressant drugs?","volume":"65","author":"Pa\u0142ucha-Poniewiera","year":"2013","journal-title":"Pharmacol. Rep."},{"issue":"9","key":"10.1016\/j.pbb.2022.173446_bb0360","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/nm1632","article-title":"Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial","volume":"13","author":"Patil","year":"2007","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.pbb.2022.173446_bb1550","doi-asserted-by":"crossref","first-page":"514","DOI":"10.2174\/1570159X13666150515234920","article-title":"The emerging role of metabotropic glutamate receptors in the pathophysiology of chronic stress-related disorders","volume":"14","author":"Peterlik","year":"2016","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.pbb.2022.173446_bb1555","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.neuropharm.2016.04.036","article-title":"Relief from detrimental consequences of chronic psychosocial stress in mice deficient for the metabotropic glutamate receptor subtype 7","volume":"115","author":"Peterlik","year":"2017","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.pbb.2022.173446_bb1560","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/npp.2015.283","article-title":"Perirhinal cortex mglu5 receptor activation reduces relapse to methamphetamine seeking by restoring novelty salience","volume":"41","author":"Peters","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2022.173446_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107831","article-title":"Targeting mGlu5 for methamphetamine use disorder","volume":"224","author":"Petzold","year":"2021","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.pbb.2022.173446_bb1565","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejphar.2005.03.028","article-title":"Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats","volume":"514","author":"Pietraszek","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2022.173446_bb1570","doi-asserted-by":"crossref","first-page":"147577","DOI":"10.1016\/j.brainres.2021.147577","article-title":"Neurochemical changes underlying cognitive impairment in olfactory bulbectomized rats and the impact of the mGlu5-positive allosteric modulator CDPPB","volume":"1768","author":"P\u0142oska","year":"2021","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/j.pbb.2022.173446_bb1575","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1124\/jpet.105.089839","article-title":"Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity","volume":"315","author":"Porter","year":"2005","journal-title":"J. Pharm. Exp. Ther."},{"issue":"7","key":"10.1016\/j.pbb.2022.173446_bb1580","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/jamapsychiatry.2016.0838","article-title":"Efficacy and safety of basimglurant as adjunctive therapy for major depression: a randomized clinical trial","volume":"73","author":"Quiroz","year":"2016","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"10.1016\/j.pbb.2022.173446_bb1585","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.parkreldis.2014.05.003","article-title":"Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias","volume":"20","author":"Rascol","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.pbb.2022.173446_bb0380","doi-asserted-by":"crossref","DOI":"10.1002\/mds.28970","article-title":"A randomized, double-blind, controlled phase II study of foliglurax in Parkinson's disease","author":"Rascol","year":"2022","journal-title":"Movement disorders : official journal of the Movement Disorder Society"},{"issue":"3","key":"10.1016\/j.pbb.2022.173446_bb0385","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1615\/CritRevEukaryotGeneExpr.2016016656","article-title":"The relevance of group II glutamate receptors expression to anxiety","volume":"26","author":"Ravid","year":"2016","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"issue":"1","key":"10.1016\/j.pbb.2022.173446_bb1590","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41398-021-01763-3","article-title":"mGluR5 binding changes during a mismatch negativity task in a multimodal protocol with [11C]ABP688 PET\/MR-EEG","volume":"12","author":"R\u00e9gio Brambilla","year":"2022","journal-title":"Transl. Psychiatry"},{"issue":"3","key":"10.1016\/j.pbb.2022.173446_bb1595","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/mds.26174","article-title":"A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease","volume":"30","author":"Reilmann","year":"2015","journal-title":"Mov. Disord. : Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.pbb.2022.173446_bb1600","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.brainres.2010.09.072","article-title":"Altered distribution of mGlu2 receptors in \u03b2-amyloid-affected brain regions of Alzheimer cases and aged PS2APP mice","volume":"1363","author":"Richards","year":"2010","journal-title":"Brain Res."},{"issue":"1152","key":"10.1016\/j.pbb.2022.173446_bb0390","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.brainres.2007.03.028","article-title":"Evaluation of the mGlu8 receptor as a putative therapeutic target in schizophrenia","volume":"4","author":"Robbins","year":"2007","journal-title":"Brain Res."},{"issue":"10","key":"10.1016\/j.pbb.2022.173446_bb1605","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/j.1365-2036.2012.05081.x","article-title":"The effects of a novel metabotropic glutamate receptor 5 antagonist (AZD2066) on transient lower oesophageal sphincter relaxations and reflux episodes in healthy volunteers","volume":"35","author":"Rohof","year":"2012","journal-title":"Alimentary Pharm. Ther."},{"issue":"4","key":"10.1016\/j.pbb.2022.173446_bb0395","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.neuron.2015.03.063","article-title":"Biased mGlu5-positive allosteric modulators provide in vivo efficacy without potentiating mGlu5 modulation of NMDAR currents","volume":"86","author":"Rook","year":"2015","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.pbb.2022.173446_bb0400","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00213-007-0758-3","article-title":"In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2\/3 receptor agonist LY404039 in animal models of psychiatric disorders","volume":"193","author":"Rorick-Kehn","year":"2007","journal-title":"Psychopharmacology"},{"issue":"8","key":"10.1016\/j.pbb.2022.173446_bb1610","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13058","article-title":"The selective metabotropic glutamate receptor 5 antagonist mavoglurant (AFQ056) reduces the incidence of reflux episodes in dogs and patients with moderate to severe gastroesophageal reflux disease","volume":"29","author":"Rouzade-Dominguez","year":"2017","journal-title":"Neurogastroenterol. Motil. : Off. J. Eur. Gastrointest. Motil. Soc."},{"issue":"2","key":"10.1016\/j.pbb.2022.173446_bb1615","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s12325-016-0468-5","article-title":"Mavoglurant augmentation in OCD patients resistant to selective serotonin reuptake inhibitors: a proof-of-concept, randomized, placebo-controlled, phase 2 study","volume":"34","author":"Rutrick","year":"2017","journal-title":"Adv. Ther."},{"issue":"4","key":"10.1016\/j.pbb.2022.173446_bb1620","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/0269881115573403","article-title":"Pharmacokinetic and pharmacodynamic characterisation of JNJ-40411813, a positive allosteric modulator of mGluR2, in two randomised, double-blind phase-I studies","volume":"29","author":"Salih","year":"2015","journal-title":"J. Psychopharmacol. (Oxford, England)"},{"key":"10.1016\/j.pbb.2022.173446_bb1625","doi-asserted-by":"crossref","first-page":"173227","DOI":"10.1016\/j.pbb.2021.173227","article-title":"Negative allosteric modulation of metabotropic glutamate receptor 5 attenuates alcohol self-administration in baboons","volume":"208","author":"Salling","year":"2021","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"100","key":"10.1016\/j.pbb.2022.173446_bb1630","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.neuropharm.2013.12.016","article-title":"Function of mGlu1 receptors in the modulation of nociceptive processing in the thalamus","volume":"79","author":"Salt","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2022.173446_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105874","article-title":"Acetyl-L-carnitine in chronic pain: a narrative review","volume":"173","author":"Sarzi-Puttini","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.pbb.2022.173446_bb1635","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.neuropharm.2014.06.013","article-title":"Negative allosteric modulation of mGlu5 receptor rescues striatal D2 dopamine receptor dysfunction in rodent models of DYT1 dystonia","volume":"85","author":"Sciamanna","year":"2014","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.pbb.2022.173446_bb1640","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/0197-0186(94)90092-2","article-title":"Novel functions for subtypes of metabotropic glutamate receptors","volume":"24","author":"Schoepp","year":"1994","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.pbb.2022.173446_bb0415","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.neuropharm.2016.07.001","article-title":"Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery","volume":"115","author":"Sengmany","year":"2017","journal-title":"Neuropharmacology"},{"issue":"1\u20133","key":"10.1016\/j.pbb.2022.173446_bb0420","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejphar.2004.08.016","article-title":"Anxiolytic-like activity of MGS0039, a potent group II metabotropic glutamate receptor antagonist, in a marble-burying behavior test","volume":"501","author":"Shimazaki","year":"2004","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.pbb.2022.173446_bb0425","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0091-3057(02)00849-3","article-title":"Group II mGluR receptor agonists are effective in persistent and neuropathic pain models in rats","volume":"73","author":"Simmons","year":"2002","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2022.173446_bb1645","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.neuropharm.2012.05.001","article-title":"Anxiolytic- but not antidepressant-like activity of Lu AF21934, a novel, selective positive allosteric modulator of the mGlu\u2084 receptor","volume":"66","author":"S\u0142awi\u0144ska","year":"2013","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.pbb.2022.173446_bb1650","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00259-018-4252-4","article-title":"Sex differences in [11C]ABP688 binding: a positron emission tomography study of mGlu5 receptors","volume":"46","author":"Smart","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.pbb.2022.173446_bb0430","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1503\/jpn.190162","article-title":"Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans","volume":"46","author":"Smart","year":"2021","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.pbb.2022.173446_bb0435","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/7854_2010_36","article-title":"Metabotropic glutamate receptors: their therapeutic potential in anxiety","volume":"2","author":"Spooren","year":"2010","journal-title":"Curr. Top. Behav. Neurosci."},{"issue":"1","key":"10.1016\/j.pbb.2022.173446_bb1655","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/14756366.2021.1998022","article-title":"New 1,2,4-oxadiazole derivatives with positive mGlu4\u202freceptor modulation activity and antipsychotic-like properties","volume":"37","author":"Stankiewicz","year":"2022","journal-title":"J. Enzyme Inhibition Med. Chem."},{"issue":"2\u20133","key":"10.1016\/j.pbb.2022.173446_bb0440","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.schres.2013.08.020","article-title":"Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo","volume":"150","author":"Stauffer","year":"2013","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.pbb.2022.173446_bb0445","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/JCP.0000000000000187","article-title":"A short-term, multicenter, placebo-controlled, randomized withdrawal study of a metabotropic glutamate 2\/3 receptor agonist using an electronic patient-reported outcome device in patients with schizophrenia","volume":"34","author":"Stauffer","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"issue":"13","key":"10.1016\/j.pbb.2022.173446_bb0450","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/mds.25561","article-title":"AFQ056 in parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study","volume":"28","author":"Stocchi","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.pbb.2022.173446_bb1660","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroimage.2021.117785","article-title":"Regional brain mGlu5 receptor occupancy following single oral doses of mavoglurant as measured by [11C]-ABP688 PET imaging in healthy volunteers","volume":"230","author":"Streffer","year":"2021","journal-title":"NeuroImage"},{"issue":"2","key":"10.1016\/j.pbb.2022.173446_bb0455","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrd1630","article-title":"Metabotropic glutamate receptors as novel targets for anxiety and stress disorders","volume":"4","author":"Swanson","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.pbb.2022.173446_bb0460","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s11307-018-1257-0","article-title":"Characterization of [11C]PXT012253 as a PET radioligand for mGlu4 allosteric modulators in nonhuman primates","volume":"21","author":"Takano","year":"2019","journal-title":"Mol. Imaging Biol."},{"issue":"6","key":"10.1016\/j.pbb.2022.173446_bb1665","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s11064-015-1595-0","article-title":"Spatial learning requires mGlu5 signalling in the dorsal hippocampus","volume":"40","author":"Tan","year":"2015","journal-title":"Neurochem. Res."},{"issue":"9","key":"10.1016\/j.pbb.2022.173446_bb1670","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/mds.26659","article-title":"A phase 2A trial of the novel mGluR5-negative allosteric modulator dipraglurant for levodopa-induced dyskinesia in Parkinson's disease","volume":"31","author":"Tison","year":"2016","journal-title":"Mov. Disord.: Off. J. Mov. Disord. Soc."},{"issue":"7","key":"10.1016\/j.pbb.2022.173446_bb1675","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/mds.26585","article-title":"Mavoglurant in Parkinson's patients with l-Dopa-induced dyskinesias: two randomized phase 2 studies","volume":"31","author":"Trenkwalder","year":"2016","journal-title":"Movement Disorders : Official Journal of the Movement Disorder Society"},{"issue":"21","key":"10.1016\/j.pbb.2022.173446_bb0465","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1042\/CS20180374","article-title":"Biased agonism and allosteric modulation of metabotropic glutamate receptor 5","volume":"132","author":"Trinh","year":"2018","journal-title":"Clin Sci (Lond)."},{"issue":"8","key":"10.1016\/j.pbb.2022.173446_bb0470","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s40263-021-00831-y","article-title":"Exploring the evidence for broad-Spectrum effectiveness of perampanel: a systematic review of clinical data in generalised seizures","volume":"35","author":"Trinka","year":"2021","journal-title":"CNS Drugs"},{"issue":"12","key":"10.1016\/j.pbb.2022.173446_bb1680","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1016\/j.clinthera.2016.10.007","article-title":"Intravenous dosing as an alternate approach to safely achieve supratherapeutic exposure for assessments of cardiac repolarization: a randomized clinical trial with mavoglurant (AFQ056)","volume":"38","author":"Ufer","year":"2016","journal-title":"Clin. Ther."},{"issue":"4","key":"10.1016\/j.pbb.2022.173446_bb1685","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.18m12470","article-title":"Randomized, double-blind, placebo-controlled trial of the mglu2\/3 negative allosteric modulator decoglurant in partially refractory major depressive disorder","volume":"81","author":"Umbricht","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pbb.2022.173446_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107809","article-title":"The pro-psychotic metabotropic glutamate receptor compounds fenobam and AZD9272 share binding sites with monoamine oxidase-B inhibitors in humans","volume":"162","author":"Varn\u00e4s","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2022.173446_bb1690","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3389\/fnmol.2018.00324","article-title":"Presynaptic mGlu1 receptors control gabab\u202freceptors in an antagonist-like manner in mouse cortical gabaergic and glutamatergic nerve endings","volume":"11","author":"Vergassola","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.pbb.2022.173446_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109022","article-title":"Exploration of group II metabotropic glutamate receptor modulation in mouse models of rett syndrome and MECP2 duplication syndrome","volume":"209","author":"Vermudez","year":"2022","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.pbb.2022.173446_bb1695","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/mp.2016.30","article-title":"Pharmacological enhancement of mGlu5 receptors rescues behavioral deficits in SHANK3 knock-out mice [published correction appears in Mol Psychiatry. 2017 May;22(5):784]","volume":"22","author":"Vicidomini","year":"2017","journal-title":"Mol. Psychiatry"},{"issue":"21","key":"10.1016\/j.pbb.2022.173446_bb1700","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1016\/j.bmc.2014.09.033","article-title":"AFQ056\/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization","volume":"22","author":"Vranesic","year":"2014","journal-title":"Bioorg. Med. Chem."},{"issue":"12","key":"10.1016\/j.pbb.2022.173446_bb0485","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/syn.20445","article-title":"Synthesis and preliminary biological evaluation of 3-[(18)F]fluoro-5-(2-pyridinylethynyl)benzonitrile as a PET radiotracer for imaging metabotropic glutamate receptor subtype 5","volume":"61","author":"Wang","year":"2007","journal-title":"Synapse"},{"issue":"6","key":"10.1016\/j.pbb.2022.173446_bb1705","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00259-017-3879-x","article-title":"A first-in-man PET study of [18F]PSS232, a fluorinated ABP688 derivative for imaging metabotropic glutamate receptor subtype 5","volume":"45","author":"Warnock","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"11","key":"10.1016\/j.pbb.2022.173446_bb0490","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1111\/bcp.14331","article-title":"Safety and pharmacokinetic profiles of MGS0274 besylate (TS-134), a novel metabotropic glutamate 2\/3 receptor agonist prodrug, in healthy subjects","volume":"86","author":"Watanabe","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.pbb.2022.173446_bb0495","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/ijnp\/pyab062","article-title":"Evaluation of the safety, tolerability, and pharmacokinetic profiles of TP0473292 (TS-161), a prodrug of a novel orthosteric mGlu2\/3 receptor antagonist TP0178894, in healthy subjects and its antidepressant-like effects in rodents","volume":"25","author":"Watanabe","year":"2022","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"8","key":"10.1016\/j.pbb.2022.173446_bb1710","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/acn3.302","article-title":"Metabotropic glutamate receptor 5: a target for migraine therapy","volume":"3","author":"Waung","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"7\u20138","key":"10.1016\/j.pbb.2022.173446_bb0500","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.neuropharm.2010.08.008","article-title":"Metabotropic glutamate receptor 4 novel agonist LSP1-2111 with anxiolytic, but not antidepressant-like activity, mediated by serotonergic and GABAergic systems","volume":"59","author":"Wiero\u0144ska","year":"2010","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.pbb.2022.173446_bb1720","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00213-011-2502-2","article-title":"Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia","volume":"220","author":"Wiero\u0144ska","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2022.173446_bb1715","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.bbr.2013.08.007","article-title":"The reversal of cognitive, but not negative or positive symptoms of schizophrenia, by the mGlu\u2082\/\u2083 receptor agonist, LY379268, is 5-HT\u2081A dependent","volume":"256","author":"Wiero\u0144ska","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pbb.2022.173446_bb1725","doi-asserted-by":"crossref","first-page":"172854","DOI":"10.1016\/j.pbb.2020.172854","article-title":"mGlu2\/3 receptor antagonism: A mechanism to induce rapid antidepressant effects without ketamine-associated side-effects","volume":"190","author":"Witkin","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"1","key":"10.1016\/j.pbb.2022.173446_bb1735","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1124\/jpet.116.238121","volume":"361","author":"Witkin","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2022.173446_bb1730","doi-asserted-by":"crossref","first-page":"173321","DOI":"10.1016\/j.pbb.2021.173321","article-title":"The imidazodiazepine, KRM-II-81: an example of a newly emerging generation of GABAkines for neurological and psychiatric disorders","volume":"213","author":"Witkin","year":"2022","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2022.173446_bb0505","article-title":"Effect of mGluR2 positive allosteric modulation on frontostriatal working memory activation in schizophrenia","author":"Wolf","year":"2021","journal-title":"Mol Psychiatry"},{"issue":"11","key":"10.1016\/j.pbb.2022.173446_bb1740","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1038\/s41380-018-0206-2","article-title":"Activation of the mGlu1\u202fmetabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M4\u202fmuscarinic receptor allosteric modulators","volume":"25","author":"Yohn","year":"2020","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.pbb.2022.173446_bb0510","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.bbrc.2004.01.073","article-title":"Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039","volume":"315","author":"Yoshimizu","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.pbb.2022.173446_bb0515","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00213-006-0390-7","article-title":"An mGluR2\/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats","volume":"186","author":"Yoshimizu","year":"2006","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.pbb.2022.173446_bb1745","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/npp.2017.177","article-title":"Effect of the mGluR5-NAM basimglurant on behavior in adolescents and adults with fragile x syndrome in a randomized, double-blind, placebo-controlled trial: fragxis phase 2 results","volume":"43","author":"Youssef","year":"2018","journal-title":"Neuropsychopharmacol. : Off. Publ. Am. Coll. Neuropsychopharmacol."},{"issue":"7","key":"10.1016\/j.pbb.2022.173446_bb0520","first-page":"6","article-title":"mGlu2 metabotropic glutamate receptors restrain inflammatory pain and mediate the analgesic activity of dual mGlu2\/mGlu3 receptor agonists","volume":"14","author":"Zammataro","year":"2011","journal-title":"Mol. Pain"},{"issue":"8","key":"10.1016\/j.pbb.2022.173446_bb1750","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1365-2982.2010.01484.x","article-title":"Efficacy, tolerability and pharmacokinetics of a modified release formulation of ADX10059, a negative allosteric modulator of metabotropic glutamate receptor 5: an esophageal pH-impedance study in healthy subjects","volume":"22","author":"Zerbib","year":"2010","journal-title":"Neurogastroenterology and Motility : The Official Journal of the European Gastrointestinal Motility Society"},{"issue":"8","key":"10.1016\/j.pbb.2022.173446_bb1755","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1365-2036.2011.04596.x","article-title":"Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastro-oesophageal reflux disease","volume":"33","author":"Zerbib","year":"2011","journal-title":"Aliment. Pharmacol. Ther."}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305722001253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305722001253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:45:03Z","timestamp":1758775503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305722001253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":241,"alternative-id":["S0091305722001253"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2022.173446","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical investigations of compounds targeting metabotropic glutamate receptors","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2022.173446","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173446"}}